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Background: Increased incidence of lung cancer among pulmonary tuberculosis patients suggests mycobacteria-induced
tumorigenic response in the host. The alveolar epithelial cells, candidate cells that form lung adenocarcinoma,
constitute a niche for mycobacterial replication and infection. We thus explored the possible mechanism of M. bovis
Bacillus Calmette-Guérin (BCG)-assisted tumorigenicity in type II epithelial cells, human lung adenocarcinoma A549 and
other cancer cells.
Methods: Cancer cell lines originating from lung, colon, bladder, liver, breast, skin and cervix were treated with tumor
necrosis factor (TNF)-α in presence or absence of BCG infection. p53, COP1 and sonic hedgehog (SHH) signaling
markers were determined by immunoblotting and luciferase assays, and quantitative real time PCR was done for
p53-responsive pro-apoptotic genes and SHH signaling markers. MTT assays and Annexin V staining were utilized to
study apoptosis. Gain- and loss-of-function approaches were used to investigate the role for SHH and COP1 signaling
during apoptosis. A549 xenografted mice were used to validate the contribution of BCG during TNF-α treatment.
Results: Here, we show that BCG inhibits TNF-α-mediated apoptosis in A549 cells via downregulation of p53
expression. Substantiating this observation, BCG rescued A549 xenografts from TNF-α-mediated tumor clearance in
nude mice. Furthermore, activation of SHH signaling by BCG induced the expression of an E3 ubiquitin ligase, COP1.
SHH-driven COP1 targeted p53, thereby facilitating downregulation of p53-responsive pro-apoptotic genes and
inhibition of apoptosis. Similar effects of BCG could be shown for HCT116, T24, MNT-1, HepG2 and HELA cells but not
for HCT116 p53−/− and MDA-MB-231 cells.
Conclusion: Our results not only highlight possible explanations for the coexistence of pulmonary tuberculosis and
lung cancer but also address probable reasons for failure of BCG immunotherapy of cancers.
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The type II alveolar epithelial cells exhibit significant
functions during mycobacterial pathogenesis. Along with
the alveolar macrophages, they are reservoirs for the
pathogenic mycobacteria in the lungs; a site suitable for
mycobacterial replication [1,2]. Additionally, these epi-
thelial cells secrete several cytokines and chemokines
that orchestrate the early host immune responses and
thus establish the intra-alveolar cytokine network [3].* Correspondence: balaji@mcbl.iisc.ernet.in
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unless otherwise stated.One of the early cytokines that could regulate epithelial
responses during mycobacterial infection is tumor necro-
sis factor (TNF)-α [4]. TNF-α is a multifunctional cytokine
that is significant for activation of macrophages and den-
dritic cells, granuloma formation and recruitment of lym-
phocytes to the infection foci during infection [5]. Of
note, TNF-α displays potent anti-tumorigenic properties
and thus used in the treatment of metastatic melanomas,
primary or metastatic unresectable liver tumors and soft
tissue sarcomas [6,7].
In this context, a large percentage of the patients with
pulmonary tuberculosis are at high risk for lung cancer,
usually adenocarcinomas [8,9]. Many studies have linkedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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caused by infection-induced inflammation and fibrosis
[10,11]. However, the exact cause and link between the
coexistence of lung adenocarcinomas and pulmonary tu-
berculosis remains obscure.
One of the significant functions of the tumor suppres-
sor p53 is to execute the apoptotic program of the cell
[12]. Hence, p53 and p53-dependent regulatory network
is the most common deregulated link in many human
cancers including the lung cancers [13]. Transactivation
properties of p53 during induction of apoptosis results
in the expression of multiple apoptotic genes like BH3-
only family PUMA, NOXA, BID and Bcl-2 family BAX
[12]. Interestingly, the turnover of p53 protein is crucial
to determine the cell-fate and is tightly regulated by
multiple E3 ubiquitin ligases and the proteasome ma-
chinery [14,15]. Various cues including treatment with
cytokines like TNF-α induces the transcriptional activa-
tion and stabilization of p53 [16].
Several signaling pathways including sonic hedgehog
(SHH) signaling, regulate the cellular homeostasis. SHH
signaling exhibits myriad functions during embryonic
development, wound healing, tissue and organ develop-
ment and infections [17]. Evidently, deregulated SHH
signaling is often associated with many human cancers
[18]. Canonical SHH signaling involves its binding to the
receptor, Patched-1 (PTCH1), alleviating the inhibition
on Smoothened (SMO). Subsequently, SMO leads to
the activation of GLI family of transcription factors
(GLI1 and GLI2). While inhibitory complex comprising
of GSK-3β is inactivated, GLI1 repressor NUMB is de-
graded. Thus, GLI1 is now functional to transactivate
the responsive genes [19].
In the current investigation, we have explored the pos-
sible mechanism of mycobacteria-assisted tumorigenicity
in type II epithelial cells, A549 human lung adenocarcin-
oma. Inhibition of TNF-α-induced apoptosis was identi-
fied as the mechanism of BCG action as assessed in A549
and several other tumor cells. Moreover, we found that
BCG activated the SHH signaling to express an E3 ubi-
quitin ligase, constitutively photomorphogenic 1 (COP1)/
RFWD2 which targets TNF-α-responsive p53 and thus
subdues apoptosis. Classical xenograft studies in nude
mice showed that BCG suppressed the TNF-α action of
tumor clearance; rather promoted tumor formation. Al-
together, our results provide the molecular basis of inhi-
bition of apoptosis, executed by mycobacteria in several
tumors to promote tumorigenesis.
Results
BCG targets p53 to rescue TNF-α-mediated cell death
To investigate the effect of mycobacterial infection on
the tumorigenic properties of alveolar epithelial cells, we
performed co-treatment of A549 cells with BCG andTNF-α, a primary cytokine produced during infection [4].
Previous reports suggest that TNF-α induces p53 expres-
sion [16] and lung cancers are often associated with
deregulated p53 [20]. We thus analyzed the expression of
p53 in the current scenario. TNF-α induced p53 expres-
sion in A549 cells as assessed by protein levels as well as
its promoter activity (Figure 1A and B). Surprisingly, in-
fection of A549 cells with BCG decreased the expression
of TNF-α-stimulated p53 (Figure 1C). p53 promoter re-
porter analysis confirmed the same (Figure 1D). p53 is a
tumor suppressor that has been strongly implicated in the
process of cell death, especially apoptosis [12]. MTT
assays confirmed the ability of BCG to rescue cells from
TNF-α-stimulated cell death (Figure 1E). Of note, TNF-α-
driven apoptosis is one of the known mechanisms of
tumor clearance [21]. Hence, we analyzed the expression
of p53-transactivated apoptotic genes such as CDKN1A/
p21, NOXA and PUMA. In accordance with the expres-
sion of p53, while the responsive genes were induced upon
TNF-α treatment, BCG suppressed TNF-α-stimulated ex-
pression of CDKN1A, NOXA and PUMA (Figure 1F). Fur-
ther, as illustrated in Figure 1G and Additional file 1:
Figure S1, TNF-α treatment induced apoptosis in lung
adenocarcinoma A549 cells. However, BCG-infected
cells inhibited TNF-α-arbitrated apoptosis as assessed
by Annexin V staining. Together, these results suggest
that TNF-α mediates apoptosis via p53 action in A549
cells and BCG surmounts this process.
BCG induces COP1 via SHH signaling to regulate
p53-mediated apoptosis
p53 turnover in the cells is often regulated by many E3
ubiquitin ligases including COP1 [15]. Therefore, we ex-
amined the expression of COP1 in response to BCG
treatment. Notably, treatment of cells with BCG resulted
in marked increase of COP1 transcripts as well as the
protein (Figure 2A,B and C). Furthermore, while BCG
failed to downregulate TNF-α-induced p53 expression in
cells transfected with COP1 siRNA (Figure 2D and E),
enforced expression of COP1 significantly reduced the
TNF-α-responsive p53 (Figure 2F) and p53-inducible
apoptotic genes (Figure 2G) in the cells. Substantiating
these results, COP1 overexpression downregulated TNF-α-
(Figure 2H) or p53- (Figure 2I) stimulated apoptosis.
We then explored the molecular mechanisms that pro-
moted BCG-driven COP1 expression in cells. Oncogenic
properties of SHH signaling are well established and re-
cent evidences suggested the role of SHH signaling in
suppressing p53-mediated apoptosis [22]. Further, BCG
was found to activate SHH signaling in macrophages to
regulate immune functions [23,24]. To determine the
contribution of SHH signaling in the current study, we
first examined the activation of SHH signaling in A549
cells on treatment with BCG. Activation of canonical
Figure 1 BCG modulates TNF-α-induced p53. (A) The expression of p53 in A549 cells treated with various concentration of TNF-α as indicated
was analyzed using immunoblotting. Adriamycin (500 ng/ml) was used as positive regulator of p53 expression. (B) The p53 promoter luciferase
construct was transfected into A549 cells and promoter activity was assayed at various concentrations of TNF-α as indicated. (C) A549 cells were
infected with BCG for 12 h prior to treatment with TNF-α. p53 expression levels were assessed by immunoblotting. (D) A549 cells were transfected
with p53 luciferase construct and change in p53 promoter activity with respect to indicated treatments was measured by luciferase assay. (E) A549
cells were treated with TNF-α alone or with BCG (MOI of 1: 25 and 1:50, 12 h) and TNF-α as shown. The MTT assay was performed at various time
points to measure the cell viability. (F) Quantitative real time RT-PCR for p53-responsive pro-apoptotic genes in A549 cells with indicated treatment.
(G) A549 cells were infected with BCG for 12 h prior to treatment with TNF-α. Representative immunofluorescence images and MFI for Annexin V-FITC
staining. Data is representative of mean ± SEM of at least 3 different experiments and all blots are representative of 3 independent experiments.
**p < 0.05 (one-way ANOVA), as compared to Med; *p < 0.05 (one-way ANOVA), as compared to TNF-α treated cells. Med, Medium.
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GLI1, GLI2, PTCH1, SMO and protein level expression
of SHH, NUMB and GSK-3β. Elevated transcripts, in-
creased SHH protein, pGSK-3β (Ser9) and decreased
NUMB indicates active SHH signaling. Utilizing these
readouts, BCG was found to induce SHH signaling in
A549 cells (Figure 3A and B). Additionally, inhibition of
SHH signaling in A549 cells by specific pharmacological
inhibitors (Figure 3C,D,E and F) or by RNA interference
of SHH (Figure 3G,H and I) abrogated BCG-induced
COP1 expression and p53 downregulation. Elevated
transcripts and promoter activity of COP1 was detectedon SHH overexpression (Figure 3J). Importantly, ChIP
assay showing recruitment of GLI1 transcription factor to
the COP1 promoter in response to BCG treatment indi-
cated that SHH signaling could regulate COP1 expression
(Figure 3K). Corroborating these observations, we found
that ability of BCG to inhibit TNF-α-stimulated apoptosis
was severely compromised in cells that were either pre-
treated with SHH inhibitors (Figure 4A) or transfected
with SHH siRNA (Figure 4B). SHH overexpression was
sufficient to significantly subdue TNF-α-mediated apop-
tosis (Figure 4C) and expression of apoptotic genes
CDKN1A, NOXA and PUMA (Figure 4D). Further,
Figure 2 BCG-induced COP1 regulates p53 expression. (A-C) A549 cells were infected with BCG at the indicated time points and analyzed for
COP1 expression by quantitative real time RT-PCR (A) and immunoblotting (B). Alternatively, COP1 promoter activity was measured by luciferase
assay (C). (D and E) Transient transfection of A549 cells with COP1 siRNA was performed and treated as indicated. Immunoblotting for p53 (D) and
validation of COP1 siRNA by immunoblotting for COP1 (E). (F and G) A549 cells were either transfected with vector (pcDNA3) or COP1 overexpression
construct (pcDNA3-COP1) and treated with TNF-α as indicated to assess the expression of p53 (F) and p53-responsive pro-apoptotic genes
(G) respectively. (H and I) A549 cells were transfected with either COP1 (H) or co-transfected with COP1 and p53 (I) overexpression constructs
and treated as shown. Apoptosis was measured by immunofluorescence microscopy for Annexin V-FITC staining. Panel shows representative
immunofluorescence images and quantitation of Annexin V-FITC MFI. Data is representative of mean ± SEM of at least 3 different experiments and
all blots are representative of 3 independent experiments. *p < 0.05 (one-way ANOVA), as compared to pcDNA3 transfected, TNF-α treated cells
(G and H) or pcDNA3 + p53-pCEP4 transfected cells (I). Med, Medium; NT, non-targeting. Bar, 20 μm.
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COP1 and p53 on BCG pretreatment of A549 cells com-
plement the observations (Figure 4E).
BCG protects tumors from TNF-α-mediated apoptosis
To evaluate these observations in vivo, we chose to
analyze the progression of human lung adenocarcinoma
A549 xenografts on co-treatment with TNF-α and BCG.
Ascertaining the cell line data, while TNF-α-treated xe-
nografts failed to exhibit sustained tumors in nude mice,
cells that were infected with BCG prior to TNF-α treat-
ment or infected with BCG alone formed significantly
larger tumors (Figure 5A,B and C). This observation wasunlike many studies that attributed anti-tumorigenic
abilities of BCG instillations [25].
Inhibition of TNF-α-orchestrated apoptosis by BCG in
tested cancers
BCG is utilized for intravesical immunotherapy for treat-
ing cancers such as bladder cancer [26,27], lung cancer
[28,29], colorectal cancer [30], melanomas [31,32] hepato-
cellular carcinoma [33] and cervical cancer [34]. However,
large proportion of the patients fails such immunothe-
rapies [27]. Further, TNF-α is also used for cancer therapy
[6,7]. Hence, with the current results, we analyzed the
effect of BCG instillation during TNF-α treatment of
Figure 3 BCG-mediated SHH signaling induce expression of COP1. (A and B) The kinetics of SHH signaling activation was assayed by
quantitative real time RT-PCR for expression of SHH signaling markers SHH, GLI1, GLI2, PTCH1 and SMO (A) and by immunoblotting for SHH, NUMB
and pGSK-3β (B). (C-F) SHH signaling was inhibited using specific pharmacological inhibitors, Cyclopamine (SMO inhibitor) and Betulinic Acid
(GLI inhibitor). Validation of inhibitors used (C) and analysis the expression of COP1 by quantitative real time RT-PCR (D), luciferase assay (E) and
immunoblotting (F). *p < 0.05 (one-way ANOVA), as compared to DMSO treated cells. (G-I) A549 cells were transfected with SHH specific siRNA to
assess COP1 and p53 protein levels after indicated treatment (G and H). Validation of SHH siRNA (I). (J) A549 cells overexpressing SHH expression
construct were analyzed for COP1 transcripts and COP1 promoter activity. *p < 0.05 (t-test), as compared to pcDNA3 transfected cells (K) A549
cells were infected with BCG and the recruitment of GLI1 transcription factor at COP1 promoter upon infection with BCG in A549 cells was
evaluated by ChIP assay. *p < 0.05 (one-way ANOVA). Data is representative of mean ± SEM, n = 3 and all blots are representative of 3 independent
experiments. Med, Medium; NT, non-targeting.
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observation, except in HCT116 p53−/− human colorectal
carcinoma cells and MDA-MB-231 human breast adeno-
carcinoma cells, infection of the HCT116 human colorec-
tal carcinoma cells, T24 human urinary bladder carcinoma
cells, MNT-1 human melanoma cells, HepG2 human
hepatocellular carcinoma cells or HELA human cervical
adenocarcinoma cells with BCG decreased the expression
of TNF-α-responsive p53 and induced the COP1 expres-
sion (Figure 5D). The expression of p53-dependent apop-
totic genes such as CDKN1A, NOXA and PUMA followed
similar trend (Figure 5E and F). Finally, the ability of BCG
to protect the tested tumor cells from TNF-α-mediated
apoptosis was also observed in HCT116, T24, MNT-1,HepG2 and HELA cells but not in HCT116 p53−/− cells
and MDA-MB-231 cells (Figure 6A and B). In conclusion,
these results suggest that inhibition of apoptosis by BCG
could fail intravesical immunotherapy.
Discussion
Interaction of the pathogenic mycobacteria with macro-
phages and epithelial cells in the alveolar spaces shape
the early responses of the infection [1,2,35]. Reports sug-
gest that apart from harboring the bacteria, infection-
induced cytokines and chemokines secreted by alveolar
type II epithelial cells recruit other immune cells such as
monocytes, lymphocytes and polymorphonuclear cells
[3]. Of note, association of pulmonary tuberculosis with
Figure 4 SHH signaling regulates apoptosis by COP1-mediated p53 degradation. (A-D) A549 cells were either pretreated with SHH
signaling specific inhibitors like Cyclopamine or Betulinic Acid followed by infection with BCG and treatment with TNF-α (A) or transfected with
SHH siRNA followed by BCG and TNF-α treatment (B) or transfected with SHH overexpression construct followed by TNF-α treatment (C and D).
Analysis of apoptosis in A549 cells determined using Annexin V staining with MFI quantitation (A-C) and by quantitative real time RT-PCR for
pro-apoptotic gene expressions (D). *p < 0.05 (one-way ANOVA), as compared to TNF-α treated cells (A); or compared to pcDNA3 transfected,
TNF-α treated cells (C); **p < 0.005 (one-way ANOVA), as compared to BCG + TNF-α treated cells and ns, not significant, as compared to TNF-α
treated SHH siRNA-transfected cells. (E) A549 cells were infected with BCG for 12 h prior to TNF-α treatment. Cells were then treated with MG132
(20 μM) for 4 h before harvest as indicated. Complexes immunoprecipitated with anti-p53, anti-UbK48 or anti-COP1 were analyzed by immunoblotting
with indicated antibodies. Data is representative of mean ± SEM of at least 3 different experiments and all blots are representative of 3 independent
experiments. Med, Medium; NT, non-targeting. Bar, 20 μm.
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fected alveolar epithelial cells in maintaining immune
and cellular homeostasis during mycobacterial infection
[8,9]. However, the mechanism of infection-induced de-
regulation is not clear. Here, we found that BCG inhibits
the TNF-α-mediated induction of a tumor suppressor,
p53 and thus promotes tumor growth.
p53 exhibits a diverse role as a tumor suppressor and
hence is called as the guardian of the genome [36]. A
number of investigations have emphasized the tumor
surveillance property of p53, especially its pro-apoptotic
functions [12,37]. In the current context, BCG targets
p53-mediated apoptosis of the cancer cells. Further,COP1 is a RING-finger containing E3-ubiquitin ligase
which can maintain the levels of multiple cellular pro-
teins including p53 [15]. Interestingly, reports suggest
that COP1 exhibits both oncogenic and tumor sup-
pressive functions depending on the cancer type [38].
Here, we find the oncogenic property of BCG-driven
COP1 to promote tumor formation and maintenance by
targeting p53.
Multiple signaling pathways are tightly regulated to as-
sert cellular homeostasis and maintenance. Deregulation
of such pathways is often implicated in several cancers
[39]. Recent studies indicate that aberrant SHH signaling
leads to tumorigenesis in several tissues by inducing
Figure 5 BCG prevents TNF-α-mediated tumor clearance and inhibits TNF-α-responsive p53 and apoptotic genes. (A-C) A549 cells were
left untreated or treated with TNF-α alone for 12 h or in combination with BCG for 12 h prior to TNF-α treatment. Treated cells (4 × 106) were
subcutaneously injected into nude mice. Tumors were harvested after 30 days. (A) Representative images of mice with subcutaneous tumors,
(B) excised tumor and (C) tumor volumes. Data is representative of mean ± SEM, *p < 0.05 (one-way ANOVA), as compared to PBS alone tumors and
**p < 0.005 (one-way ANOVA), as compared to TNF-α treated tumors. (D) The indicated cell lines were infected with BCG for 12 h prior to treatment
with TNF-α. p53 and COP1 expression levels were assessed by immunoblotting. (E and F) Quantitative real time RT-PCR for p53-responsive
pro-apoptotic genes CDKN1A, NOXA and PUMA in different cell lines with indicated treatment. Data is representative of mean ± SEM of at least 3
different experiments and all blots are representative of 3 independent experiments. *p < 0.05 (one-way ANOVA) and ns, not significant, as
compared to TNF-α treated cells. Med, Medium.
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context, ability of BCG to activate cellular signaling
pathways including SHH cascade is well evidenced in
macrophages [23,40,41]. In the present study, we found
that BCG could elevate SHH signaling in A549 cells.
Supporting the previous observation [22], the induced
SHH signaling inhibits p53-stimulated apoptosis. Not-
ably, COP1 expression is found to be SHH-dependent.
COP1 targets p53 for degradation and thus regulates
p53-responsive functions.
The history of BCG immunotherapy dates as early as
1976 when Morales and colleagues found its potential to
treat superficial bladder cancer [42]. Further, BCG went
on to be the first FDA-approved immunotherapy [43].
For a few decades now, BCG immunotherapy is either astandard treatment or constitutes the treatment regime
for several cancers. Though the success of such therapies
has been tremendous, a significant set of the patients fail
BCG therapy. In case of bladder cancer, while 20-30% of
patients fail the therapy, 30-50% of them exhibit tumor
recurrence [27]. Such cases of failed adjuvant or neo-
adjuvant BCG therapies and tumor recurrence during
various human cancer treatment regimes have initiated
alternative or complementary therapies [44]. While se-
veral mechanisms of action of BCG immunotherapies
have been proposed and tested, we lack clear under-
standing on the reasons for failed therapies [26]. In the
present investigation, we found that the ability of BCG
to inhibit apoptosis of cancer cells could be one of the
probable reasons that hinder tumor clearance during
Figure 6 BCG inhibits TNF-α-mediated apoptosis. (A and B) HCT116, HCT116 p53−/−, T24, MNT-1, HepG2, HELA and MDA-MB-231 cells were
infected with BCG for 12 h prior to treatment with TNF-α. Representative immunofluorescence images (A) and MFI (B) for Annexin V-FITC staining.
Data is representative of mean ± SEM of at least 3 different experiments. *p < 0.05 (one-way ANOVA) and ns, not significant, as compared to TNF-α
treated cells. Med, Medium. Bar, 20 μm.
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matory responses during infection, there are multiple ev-
idences of anti-inflammatory Th2 and regulatory T cell
(Treg) functions stimulated by BCG [45,46]. Inte-
restingly, both Th2 and Treg cells exhibit pro-tumor
effects in cancers [47,48]. Evasion of protective immune
responses by BCG could also contribute to failed
immunotherapy.
Application of TNF-α as potent cytokine for cancer
biotherapy is due to its ability to mediate functions such
as apoptosis. To overcome the systemic toxicity asso-
ciated with such treatments, various strategies including
cell-based therapies and gene therapies are under study
which aims at site-specific expression of TNF-α [44].
Our study indicates that BCG downregulates TNF-α-
arbitrated apoptosis in the tested human cancer cell
lines, A549, HCT116, T24, MNT-1, HepG2 and HELA.
Interestingly, results in MDA-MB-231 human breast
adenocarcinoma cells and HCT116 p53−/− human colo-
rectal carcinoma cells were the outliers. While absence
of p53 can be attributed to the reduced TNF-α re-
sponses and diminished p53 functions in HCT116
p53−/− cells, the possible reasons for the observations inMDA-MB-231 with mutant p53 is currently under in-
vestigation. Further, though BCG treatment, by itself,
can induce the expression of TNF-α in immune cells
[23] and during BCG therapy [49], in the current study we
addressed the ability of BCG to revert the TNF-α re-
sponses such as apoptosis during therapy. However, BCG
failed to protect A549 cells against apoptosis induced by
other death ligands of the TNF family such as TRAIL
(Additional file 2: Figure S2). This observation is in line
with the available literature that suggests that TRAIL in-
duces apoptosis regardless of the p53 status in the cells
[50]. Further, the specificity of the response was also
assessed in macrophages, the main host ofMycobacterium.
BCG infection of PMA-stimulated THP-1 macrophages
failed to protect the cells from TNF-α-mediated apoptosis
(Additional file 3: Figure S3). This observation is in line
with existing literatures that suggest that BCG induces
apoptosis of the infected macrophages [51-53]. However,
TNF-α-induced p53 expression was slightly downregulated
during BCG infection of THP-1 cells. This suggests that
there could be p53-independent mechanisms that BCG
adopts for inducing apoptosis in macrophages [53]. In-
terestingly, treatment of A549 cells with BCG lysate,
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R848 (a TLR7/8 agonist) showed induced COP1 expres-
sion and corresponding inhibition of TNF-α-mediated p53
expression (Additional file 4: Figure S4A). However, except
for LPS treatment, induction of apoptosis by TNF-α was
downregulated by BCG lysate, Pam3CSK4 and R848
(Additional file 4: Figure S4B and C). This suggests that
stimulation of TLR1/2/7/8 could lead to suppression of
TNF-α-mediated responses in A549 cells.
Conclusion
In summary, we show that BCG suppressed the apoptotic
functions of TNF-α in many cancer cell lines thereby pro-
moting tumorigenesis. Here, SHH-responsive E3 ligase
COP1 aids in downregulating the TNF-α-driven p53
expression and functions (Figure 7). Our results suggest
that inhibition of apoptosis by M. bovis BCG could re-
sult in unsuccessful intravesical immunotherapy. Thus
the study underscores the need for alternate agents for
immunotherapy.
Methods
Cell-lines and bacteria
A549 human lung adenocarcinoma, HCT116, HCT116
p53−/− human colorectal carcinoma, HELA human
cervical adenocarcinoma cell lines and THP-1 human
monocytic cells were cultured in DMEM (Gibco-Life
Technologies, Carlsbad, CA, USA) containing 10% FBSFigure 7 Model. TNF-α regulates the progression of cancers by promoting
SHH signaling-dependent expression of COP1, a regulator of p53 activity. C
These events culminate into inhibition of apoptosis and promotion of tum(Gibco-Life Technologies). T24 human urinary bladder
carcinoma cells were cultured in McCoy’s 5A modified
medium (Sigma-Aldrich, St. Louis, MO, USA). MNT-1
human melanoma cell line was maintained in MNT-1
media containing DMEM supplemented with 10%
AIMV medium, 15% FBS, 1% glutamine, 1% sodium
pyruvate and 1% non-essential amino acids (all from
Gibco-Life Technologies). HepG2 human hepato-
cellular carcinoma cell line was cultured in EMEM
(Sigma-Aldrich) containing 10% FBS. M. bovis BCG
Pasteur 1173P2 was obtained from Pasteur Institute,
Paris, France. BCG-RFP was generated in the lab.
Bacteria were grown to mid-log phase and used at 10
multiplicity of infection (MOI) in all the experiments.
Reagents and antibodies
General laboratory chemicals were obtained from Sigma-
Aldrich or Merck Millipore (Darmstadt, Germany). TNF-α
and TRAIL were purchased from PeproTech Inc (Rocky
Hill, NJ, USA). Pam3CSK4, LPS and R848 were pur-
chased from ImmunoTools (Friesoythe, Germany). Anti-
β-ACTIN antibody was bought from Sigma-Aldrich.
Anti-p53 and anti-COP1 antibodies were obtained from
Santa Cruz Biotechnology Ltd (Dallas, Texas, USA).
Anti-SHH, anti-GLI1, anti-PTCH1, anti-NUMB, anti-Ser9
phospho GSK-3β and anti-UbK48 were purchased from
Cell Signaling Technology (Danvers, MA, USA). Annexin
V- fluorescein isothiocyanate (FITC) was from Miltenyip53-dependent apoptosis. However, the presence of BCG induces
OP1 targets p53 for ubiquitin-mediated proteasomal degradation.
origenicity.
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anti-rabbit IgG and anti-mouse IgG were obtained from
Jackson ImmunoResearch (West Grove, PA, USA).
Xenografts in nude mice
Nude mice (nu/nu) were maintained in the Central
Animal Facility, Indian Institute of Science. All studies
involving mice were carried out after the approval from
the Institutional Ethics Committee for Animal Experi-
mentation as well as from Institutional Biosafety Com-
mittee. Subcutaneous injection of mice with 4 × 106
A549 cells into its right flank was carried out. The xeno-
grafts were monitored regularly for a period of 30 days
and tumor sizes were measured with a caliper. After
30 days, tumors were excised and the tumor volume was
measured by the formulae V = (LxW2) × 0.52, where V is
volume, L is length, W is width.
Treatment with pharmacological reagents
In the experiments utilizing inhibitors, cells were treated
with the given inhibitor for 1 h before the experimen-
tal treatments at following concentrations: Cyclopamine
(10 μM), Betulinic Acid (10 μM) (both from Calbiochem-
Merck Millipore, Darmstadt, Germany). DMSO at 0.1%
concentration was used as the vehicle control. In all experi-
ments involving pharmacological reagents, a tested con-
centration was used after careful titration experiments
assessing the viability of the cells using the MTT (3-(4,5-Di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay.
MTT assay
Survival of the A549 cells were evaluated by MTT assay
as described previously [54]. Briefly, a cell density of 1.5
× 103/well was seeded in a 96-well plate and the expe-
riment was carried out. 20 μl of 5 mg/ml MTT reagent
was added to the wells 3 h prior to the completion of
the experiment. The formazan crystals formed in the
living cells were dissolved in 200 μl of DMSO which was
added to the washed cells. Absorbance of the solu-
tion was measured at 550 nm using an ELISA reader
(Molecular Devices, Sunnyvale, CA, USA).
Transfection studies
A549 cells were transiently transfected with 5 μg of
COP1, p53, SHH or β-galactosidase overexpression con-
structs or COP1, p53 luciferase constructs using low
m.w. polyethylenimine (Sigma-Aldrich). In case of experi-
ments involving siRNA, A549 cells were transfected with
100 nM siRNA. SHH, GLI1, COP1, non-targeting siRNA
and siGLO Lamin A/C were obtained from Dharmacon,
Inc. (Lafayette, CO, USA) as siGENOME™ SMARTpool
reagents, which contain a pool of four different double-
stranded RNA oligonucleotides. Transfection efficiency
was found to be more than 70% in all the experiments asdetermined by counting the number of siGLO Lamin A/C
positive cells. In all cases, 48 h post-transfection, the cells
were treated as indicated and processed for analysis.
Immunofluorescence
Cells were seeded on to coverslips and treated as indi-
cated. Annexin V-FITC staining was carried out according
to manufacturer’s instructions. The cells were fixed with
3.7% paraformaldehyde for 15 min at room temperature
and the coverslips were mounted on a slide with glycerol.
Confocal images were taken on Zeiss LSM 710 and Zeiss
LSM 510 Meta confocal laser scanning microscopes
(Carl Zeiss AG, Oberkochen, Germany) using a plan-
Apochromat 63X/1.4 Oil DIC objective and images were
analyzed using ZEN 2009 software (Carl Zeiss AG).
RNA isolation and quantitative real time RT-PCR
Total RNA from experimentally treated cell lines was iso-
lated using TRI reagent (Sigma-Aldrich). 2 μg of total
RNA was converted into cDNA using First strand cDNA
synthesis kit (Bioline, London, UK). Quantitative real time
RT-PCR for quantification of the target gene expression
was performed using SYBR Green PCR mixture (KAPA
Biosystems, Woburn, MA, USA). All the experiments
were repeated at least three times independently to ensure
the reproducibility of the results. GAPDH was used as in-
ternal control. Additional file 5: Table S1 contains the
primers used for quantitative real time RT-PCR.
Immunoblotting
RIPA buffer [50 mM Tris–HCl (pH 7.4), 1% NP-40, 0.25%
Sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM
PMSF, 1 μg/ml of each aprotinin, leupeptin, pepstatin,
1 mM Na3VO4 and 1 mM NaF] was used to obtain the
total cell lysates. Protein in each sample was estimated
using Bradford assay; equal amount of protein was resolved
on a 12% SDS-polyacrylamide gel and transferred to
polyvinylidene difluoride (PVDF) membranes (Millipore)
by the semi-dry transfer (Bio-Rad, Hercules, CA, USA)
method. Blocking with 5% nonfat dry milk powder in
TBST [20 mM Tris–HCl (pH 7.4), 137 mM NaCl, and
0.1% Tween 20] for 60 min was done to prevent nonspe-
cific binding. The blots were incubated overnight at 4°C
with primary antibody followed by incubation with anti-
rabbit-HRP or anti-mouse-HRP secondary antibody in 5%
BSA for 2 h. The immunoblots were developed with en-
hanced chemiluminescence detection system (PerkinElmer,
Waltham, MA, USA) as per manufacturer’s instructions.
β-ACTIN was used as loading control. Blots were incu-
bated in the stripping buffer [62.5 mM Tris–HCl (pH 6.8),
2% SDS and 0.7% β-mercaptoethanol] at 60°C on a shaker
for probing another protein in the same region of the
PVDF membrane.
Holla et al. Molecular Cancer 2014, 13:210 Page 11 of 13
http://www.molecular-cancer.com/content/13/1/210Luciferase assays
Transfected cells were lysed in Reporter lysis buffer
(Promega, Madison, WI, USA) and assayed for luciferase
activity using Luciferase Assay Reagent (Promega) as per
the manufacturer’s instructions. β-galactosidase activity
utilizing O-nitrophenol β-D-galactopyranoside (HiMedia
Laboratories Pvt Ltd, Mumbai, Maharashtra, India) was
performed to normalize the transfection efficiencies.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assay was carried
out using a protocol provided by Upstate Biotechnology,
Inc. (Lake Placid, NY, USA), with certain modifications.
Briefly, cells were fixed with 1.42% formaldehyde for
15 min at room temperature followed by inactivation of
formaldehyde using 125 mM glycine. Modified RIPA buf-
fer containing 1% Triton X-100 was used for cell lysis and
samples were sonicated to obtain sheared chromatin frag-
ments of 500 bp. Anti-GLI1 or rabbit preimmune sera
immunoprecipitated DNA was purified and analyzed by
quantitative PCR. All results were normalized to ampli-
fication of 28S rRNA. ChIP experiments were repeated at
least three times and the primers utilized are listed in
Additional file 5: Table S1.
Immunoprecipitation assay
Immunoprecipitation (IP) assays were carried out using
protocol provided by Millipore with certain modifications.
Briefly, the cells were gently lysed in ice-cold RIPA buffer
on an orbital shaker. The cell lysates were incubated with
anti-UbK48, anti-p53, anti-COP1 or rabbit preimmune
sera at 4°C for 2 h on an orbital shaker. The immunocom-
plexes were captured using Protein A (Bangalore Genei)
agarose at 4°C for 2 h. The beads were harvested, washed,
and boiled in 5× Laemmli buffer for 10 min. The samples
were separated by SDS-PAGE and further subjected for
immunoblotting.
Statistical analysis
Levels of significance for comparison between samples
were determined by the Student t test distribution and
one-way ANOVA. The data in the graphs are expressed
as the mean ± SEM for 5 or 6 values from 3 independent
experiments and p values < 0.05 were defined as signifi-
cant. GraphPad Prism 5.0 software (GraphPad Software,
Inc., San Diego, CA, USA) was used for all the statistical
analysis.
Additional files
Additional file 1: Figure S1. BCG inhibits TNF-α-induced apoptosis.
(A) A549 cells were infected with BCG-RFP for 12 h prior to TNF-α
treatment. Representative immunofluorescence images for AnnexinV-FITC staining and BCG-RFP. Data is representative of 3 different
experiments. Med, Medium. Bar, 5 μm.
Additional file 2: Figure S2. BCG failed to downregulate TRAIL-induced
apoptosis. (A) A549 cells were infected with BCG for 12 h prior to treatment
with 20 ng/ml TRAIL. Representative immunofluorescence images and MFI
for Annexin V-FITC staining. Data is representative of mean ± SEM of at least
3 different experiments. ns, not significant, as compared to TNF-α treated
cells. Med, Medium. Bar, 20 μm.
Additional file 3: Figure S3. BCG failed to downregulate TNF-α-induced
apoptosis in macophages. (A and B) PMA-stimulated THP-1 cells were
infected with BCG for 12 h prior to TNF-α treatment. Expression of p53 and
COP1 were assessed by immunoblotting with total cell lysate (A) and
representative immunofluorescence images and MFI for Annexin V-FITC
staining (B). Data is representative of mean ± SEM of at least 3 different
experiments and all blots are representative of 3 independent experiments.
ns, not significant, as compared to TNF-α treated cells. Med, Medium. Bar,
20 μm.
Additional file 4: Figure S4. Ability of various innate receptor agonists
to inhibit TNF-α-induced apoptosis. (A-C) A549 cells were either infected
with BCG or stimulated with BCG lysate, Pam3CSK4 (1 μg/ml), LPS
(50 ng/ml) or R848 (1 μg/ml) for 12 h prior to treatment with TNF-α.
Immunoblotting analysis of p53 and COP1 (A) and MFI (B) and representative
immunofluorescence images (C) for Annexin V-FITC staining. Data is
representative of mean ± SEM of at least 3 different experiments and all blots
are representative of 3 independent experiments. *p < 0.05 (one-way
ANOVA) and ns, not significant, as compared to TNF-α treated cells. Med,
Medium. Bar, 20 μm.
Additional file 5: Table S1. Primers used in the study.Abbreviations
BCG: M. bovis Bacillus Calmette-Guérin; ChIP: Chromatin immunoprecipitation;
COP1: Constitutively photomorphogenic 1; IP: Immunoprecipitation;
MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;
PTCH1: Patched-1; SMO: Smoothened; SHH: Sonic hedgehog;
Treg: Regulatory T cell; TNF: Tumor necrosis factor.
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